CRP drug combo for older adults with untreated double-positive DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older, OR you are 60-69 with a health score of 2-4 on a standard scale (limited daily activity).
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL) that is CD20-positive and also has both C-MYC and Bcl-2 turned on (double-expressor).
- You have not had any previous treatment for this lymphoma, like chemo, targeted therapy, immunotherapy, or surgery (except a small biopsy).
- You have at least one tumor that can be seen on a PET-CT scan.
- Your blood counts and liver/kidney function are within a certain range (your doctor can check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This study tests whether a combination of two drugs (pomalidomide and rituximab) can help prevent lymphoma from coming back after initial treatment. It is for younger patients with high-risk DLBCL who responded well to their first therapy.
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
This trial tests a combination of three drugs for newly diagnosed older adults with a specific type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this treatment is safe and effective for patients who may not be able to tolerate standard chemotherapy.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.